{"protocolSection": {"identificationModule": {"nctId": "NCT00636207", "orgStudyIdInfo": {"id": "0476-380"}, "secondaryIdInfos": [{"id": "2008_516", "type": "OTHER", "domain": "Merck Registration ID"}], "organization": {"fullName": "Organon and Co", "class": "INDUSTRY"}, "briefTitle": "A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Inhaled Montelukast (MK-0476) in Participants With Mild or Moderate Asthma (MK-0476-380 AM3)(COMPLETED)", "officialTitle": "A Sequential, 3-Part, Double-Blind, Randomized, Placebo-Controlled, Single-Rising-Dose and Rising-Multiple-Dose Study in Healthy Subjects and Mild or Moderate Asthmatic Patients to Evaluate the Safety, Tolerability, and Pharmacokinetics of Inhaled MK-0476"}, "statusModule": {"statusVerifiedDate": "2022-02", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2007-08"}, "primaryCompletionDateStruct": {"date": "2008-09", "type": "ACTUAL"}, "completionDateStruct": {"date": "2008-10", "type": "ACTUAL"}, "studyFirstSubmitDate": "2008-03-03", "studyFirstSubmitQcDate": "2008-03-07", "studyFirstPostDateStruct": {"date": "2008-03-14", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2012-12-20", "resultsFirstSubmitQcDate": "2012-12-20", "resultsFirstPostDateStruct": {"date": "2013-01-28", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2024-05-07", "lastUpdatePostDateStruct": {"date": "2024-05-09", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Organon and Co", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "A study to evaluate the safety, tolerability and pharmacokinetics of inhaled Montelukast (MK-0476) in participants with mild or moderate asthma."}, "conditionsModule": {"conditions": ["Asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 46, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Montelukast 0.1 mg", "type": "EXPERIMENTAL", "description": "Participants receive Montelukast inhalation powder, 0.1 mg.\n\n* Part I: Administered as a single dose followed by at least a 3-day washout period.", "interventionNames": ["Drug: Montelukast"]}, {"label": "Montelukast 0.3 mg", "type": "EXPERIMENTAL", "description": "Participants receive Montelukast inhalation powder, 0.3 mg.\n\n* Part I: Administered as a single dose followed by at least a 3-day washout period.", "interventionNames": ["Drug: Montelukast"]}, {"label": "Montelukast 1 mg", "type": "EXPERIMENTAL", "description": "Participants receive Montelukast inhalation powder, 1 mg.\n\n* Part I: Administered as a single dose followed by at least a 3-day washout period.\n* Part II: Administered once daily (QD) for 5 days followed by at least a 3-day washout period.", "interventionNames": ["Drug: Montelukast"]}, {"label": "Montelukast 3 mg", "type": "EXPERIMENTAL", "description": "Participants receive Montelukast inhalation powder, 3 mg.\n\n* Part I: Administered as a single dose followed by at least a 3-day washout period.\n* Part II: Administered QD for 5 days followed by at least a 3-day washout period.\n* Part III: Administered QD for 10 days followed by at least a 7-day washout period.", "interventionNames": ["Drug: Montelukast"]}, {"label": "Montelukast 10 mg", "type": "EXPERIMENTAL", "description": "Participants receive Montelukast inhalation powder, 10 mg.\n\n* Part I: Administered as a single dose followed by at least a 3-day washout period.\n* Part II: Administered QD for 5 days followed by at least a 3-day washout period.\n* Part III: Administered QD for 10 days followed by at least a 7-day washout period.", "interventionNames": ["Drug: Montelukast"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Participants receive Placebo to Montelukast inhalation powder.\n\n* Part I: Administered as a single dose followed by at least a 3-day washout period.\n* Part II: Administered QD for 5 days followed by at least a 3-day washout period.\n* Part III: Administered QD for 10 days followed by at least a 7-day washout period.", "interventionNames": ["Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "Montelukast", "description": "Montelukast dry powder inhaler, 0.1 mg, 0.3 mg, 1 mg, 3 mg or 10 mg", "armGroupLabels": ["Montelukast 0.1 mg", "Montelukast 0.3 mg", "Montelukast 1 mg", "Montelukast 10 mg", "Montelukast 3 mg"], "otherNames": ["Montelukast Sodium", "MK-0476"]}, {"type": "DRUG", "name": "Placebo", "description": "Placebo dry powder inhaler", "armGroupLabels": ["Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Number of Participants Who Experienced At Least One Adverse Event", "timeFrame": "Up to 14 days after last dose of study drug"}, {"measure": "Number of Participants Who Discontinued Study Drug Due to an Adverse Event", "timeFrame": "Up to 7 days after last dose of study drug"}, {"measure": "Area Under the Curve From 0 to 24 Hours (AUC 0-24hr) of Montelukast - Single Dose", "description": "Blood samples for assessment of AUC 0-24hr were drawn predose and then at specified timepoints (up to 24 hours postdose) on Day 1 in Part I.", "timeFrame": "Up to 24 hours postdose"}, {"measure": "AUC 0-24hr of Montelukast - Multiple Doses", "description": "Blood samples for assessment of AUC 0-24hr were drawn predose and then at specified timepoints (up to 24 hours postdose) on Days 1 and 5 in Part II and on Days 1 and 10 in Part III.", "timeFrame": "Up to 24 hours postdose"}, {"measure": "Maximum Plasma Concentration (Cmax) of Montelukast - Single Dose", "description": "Blood samples for assessment of Cmax were drawn predose and then at specified timepoints (up to 24 hours postdose) on Day 1 in Part I.", "timeFrame": "Up to 24 hours postdose"}, {"measure": "Cmax of Montelukast - Multiple Doses", "description": "Blood samples for assessment of Cmax were drawn predose and then at specified timepoints (up to 24 hours postdose) on Days 1 and 5 in Part II and on Days 1 and 10 in Part III.", "timeFrame": "Up to 24 hours postdose"}, {"measure": "Time to Cmax (Tmax) of Montelukast - Single Dose", "description": "Blood samples for assessment of Tmax were drawn predose and then at specified timepoints (up to 24 hours postdose) on Day 1 in Part I.", "timeFrame": "Up to 24 hours postdose"}, {"measure": "Tmax of Montelukast - Multiple Doses", "description": "Blood samples for assessment of Tmax were drawn predose and then at specified timepoints (up to 24 hours postdose) on Days 1 and 5 in Part II and on Days 1 and 10 in Part III.", "timeFrame": "Up to 24 hours postdose"}, {"measure": "Apparent Terminal Half Life (t1/2) of Montelukast - Single Dose", "description": "Blood samples for assessment of t1/2 were drawn predose and then at specified timepoints (up to 24 hours postdose) on Day 1 in Part I.", "timeFrame": "Up to 24 hours postdose"}, {"measure": "t1/2 of Montelukast - Multiple Doses", "description": "Blood samples for assessment of t1/2 were drawn predose and then at specified timepoints (up to 24 hours postdose) on Days 1 and 5 in Part II and on Days 1 and 10 in Part III.", "timeFrame": "Up to 24 hours postdose"}, {"measure": "AUC 0-24hr Accumulation Ratio of Montelukast - Multiple Doses", "description": "The AUC 0-24hr Accumulation Ratio of Montelukast was calculated as the geometric mean ratio of AUC 0-24hr on the last day and the first day of a multiple dose regimen: Day 5/Day 1 in Part II and Day 10/Day 1 in Part III.", "timeFrame": "up to 10 days after first dose of study drug"}, {"measure": "Cmax Accumulation Ratio of Montelukast - Multiple Doses", "description": "The Cmax Accumulation Ratio of Montelukast was calculated as the geometric mean ratio of Cmax on the last day and the first day of a multiple dose regimen: Day 5/Day 1 in Part II and Day 10/Day 1 in Part III.", "timeFrame": "up to 10 days after first dose of study drug"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Male or female between the ages of 18 and 65\n* Must have mild or moderate asthma (Part III only)\n* Nonsmoker for at least 6 months\n\nExclusion Criteria:\n\n* History of stroke, chronic seizures or major neurological disorder\n* You are nursing\n* Drink more than 3 glasses of alcohol a day\n* Have allergy to or not able to tolerate lactose\n* Have a history of drug abuse in the last 5 years\n* Drink more than 6 beverages containing caffeine a day\n* Have had surgery, donated blood or participated in another investigational study in the last 4 weeks", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "65 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Medical Monitor", "affiliation": "Merck Sharp & Dohme LLC", "role": "STUDY_DIRECTOR"}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "resultsSection": {"participantFlowModule": {"recruitmentDetails": "Participants were recruited from 3 study sites located in the United States.", "groups": [{"id": "FG000", "title": "Part I - Montelukast", "description": "Part I consisted of 6 periods. Participants were to receive single doses of inhaled Montelukast (0.1 mg, 0.3 mg, 0.3 mg repeat, 1 mg, 3 mg or 10 mg). Each dose was separated by at least a 3-day washout period."}, {"id": "FG001", "title": "Part I - Montelukast and Placebo", "description": "Part I consisted of 6 periods. Participants were to receive single doses of inhaled Montelukast (0.1 mg, 0.3 mg, 0.3 mg repeat, 1 mg, 3 mg or 10 mg) or Placebo. Each dose was separated by at least a 3-day washout period."}, {"id": "FG002", "title": "Part II - Montelukast", "description": "Part II consisted of 3 periods. Participants in three serial panels (Panels A, B and C) were to receive once daily (QD) doses of inhaled Montelukast (1 mg, 3 mg or 10 mg) administered for 5 consecutive days. Each panel was separated by at least a 3-day washout period."}, {"id": "FG003", "title": "Part II - Placebo", "description": "Part II consisted of 3 periods. Participants in three serial panels (Panels A, B and C) were to receive QD doses of inhaled Placebo administered for 5 consecutive days. Each panel was separated by at least a 3-day washout period."}, {"id": "FG004", "title": "Part III - Montelukast", "description": "Part III consisted of 2 periods. Participants in two serial panels (Panels A and B) were to receive QD doses of inhaled Montelukast (3 mg or 10 mg) administered for 10 consecutive days. Each panel was separated by at least a 7-day washout period."}, {"id": "FG005", "title": "Part III - Montelukast and Placebo", "description": "Part III consisted of 2 periods. Participants in two serial panels (Panels A and B) were to receive QD doses of inhaled Montelukast (3 mg or 10 mg) or Placebo administered for 10 consecutive days. Each panel was separated by at least a 7-day washout period."}, {"id": "FG006", "title": "Part III - Placebo", "description": "Part III consisted of 2 periods. Participants in two serial panels (Panels A and B) were to receive QD doses of inhaled or Placebo administered for 10 consecutive days. Each panel was separated by at least a 7-day washout period."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "comment": "One participant discontinued after completing Period 2. Doses in Periods 1 and 2 were Montelukast.", "numSubjects": "1"}, {"groupId": "FG001", "comment": "One participant withdrew consent after completing all study doses.", "numSubjects": "8"}, {"groupId": "FG002", "numSubjects": "18"}, {"groupId": "FG003", "numSubjects": "6"}, {"groupId": "FG004", "comment": "One participant withdrew consent after completing all study doses.", "numSubjects": "9"}, {"groupId": "FG005", "numSubjects": "1"}, {"groupId": "FG006", "numSubjects": "3"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "7"}, {"groupId": "FG002", "numSubjects": "18"}, {"groupId": "FG003", "numSubjects": "6"}, {"groupId": "FG004", "numSubjects": "8"}, {"groupId": "FG005", "numSubjects": "1"}, {"groupId": "FG006", "numSubjects": "3"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "1"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "1"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Part I", "description": "Part I consisted of 6 periods. Participants were to receive single doses of inhaled Montelukast (0.1 mg, 0.3 mg, 0.3 repeat, 1 mg, 3 mg or 10 mg) or Placebo. Each dose was separated by at least a 3-day washout period."}, {"id": "BG001", "title": "Part II", "description": "Part II consisted of 3 periods. Participants in three serial panels (Panels A, B and C) were to receive once daily (QD) doses of inhaled Montelukast (1 mg, 3 mg or 10 mg) or Placebo administered for 5 consecutive days. Each panel was separated by at least a 3-day washout period."}, {"id": "BG002", "title": "Part III", "description": "Part III consisted of 2 periods. Participants in two serial panels (Panels A and B) were to receive QD doses of inhaled Montelukast (3 mg or 10 mg) or Placebo administered for 10 consecutive days. Each panel was separated by at least a 7-day washout period."}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "9"}, {"groupId": "BG001", "value": "24"}, {"groupId": "BG002", "value": "13"}, {"groupId": "BG003", "value": "46"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "37.4", "spread": "10.45"}, {"groupId": "BG001", "value": "31.0", "spread": "12.68"}, {"groupId": "BG002", "value": "36.3", "spread": "10.32"}, {"groupId": "BG003", "value": "33.8", "spread": "11.78"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "14"}, {"groupId": "BG002", "value": "6"}, {"groupId": "BG003", "value": "22"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "10"}, {"groupId": "BG002", "value": "7"}, {"groupId": "BG003", "value": "24"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Number of Participants Who Experienced At Least One Adverse Event", "populationDescription": "Safety Population: All participants who received at least one dose of study drug", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Up to 14 days after last dose of study drug", "groups": [{"id": "OG000", "title": "Montelukast 0.1 mg", "description": "Participants receiving Montelukast 0.1 mg inhalation powder"}, {"id": "OG001", "title": "Montelukast 0.3 mg", "description": "Participants receiving Montelukast 0.3 mg inhalation powder"}, {"id": "OG002", "title": "Montelukast 1 mg", "description": "Participants receiving Montelukast 1 mg inhalation powder"}, {"id": "OG003", "title": "Montelukast 3 mg", "description": "Participants receiving Montelukast 3 mg inhalation powder"}, {"id": "OG004", "title": "Montelukast 10 mg", "description": "Participants receiving Montelukast 10 mg inhalation powder"}, {"id": "OG005", "title": "Placebo", "description": "Participants receiving Placebo inhalation powder"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "7"}, {"groupId": "OG002", "value": "12"}, {"groupId": "OG003", "value": "18"}, {"groupId": "OG004", "value": "19"}, {"groupId": "OG005", "value": "18"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "4"}, {"groupId": "OG002", "value": "6"}, {"groupId": "OG003", "value": "9"}, {"groupId": "OG004", "value": "5"}, {"groupId": "OG005", "value": "6"}]}]}]}, {"type": "PRIMARY", "title": "Number of Participants Who Discontinued Study Drug Due to an Adverse Event", "populationDescription": "Safety Population: All participants who received at least one dose of study drug", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Up to 7 days after last dose of study drug", "groups": [{"id": "OG000", "title": "Montelukast 0.1 mg", "description": "Participants receiving Montelukast 0.1 mg inhalation powder"}, {"id": "OG001", "title": "Montelukast 0.3 mg", "description": "Participants receiving Montelukast 0.3 mg inhalation powder"}, {"id": "OG002", "title": "Montelukast 1 mg", "description": "Participants receiving Montelukast 1 mg inhalation powder"}, {"id": "OG003", "title": "Montelukast 3 mg", "description": "Participants receiving Montelukast 3 mg inhalation powder"}, {"id": "OG004", "title": "Montelukast 10 mg", "description": "Participants receiving Montelukast 10 mg inhalation powder"}, {"id": "OG005", "title": "Placebo", "description": "Participants receiving Placebo inhalation powder"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "7"}, {"groupId": "OG002", "value": "12"}, {"groupId": "OG003", "value": "18"}, {"groupId": "OG004", "value": "19"}, {"groupId": "OG005", "value": "18"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}, {"groupId": "OG005", "value": "0"}]}]}]}, {"type": "PRIMARY", "title": "Area Under the Curve From 0 to 24 Hours (AUC 0-24hr) of Montelukast - Single Dose", "description": "Blood samples for assessment of AUC 0-24hr were drawn predose and then at specified timepoints (up to 24 hours postdose) on Day 1 in Part I.", "populationDescription": "Per Protocol Population: All participants who complied with the protocol", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng/mL*hr", "timeFrame": "Up to 24 hours postdose", "groups": [{"id": "OG000", "title": "Montelukast 0.1 mg", "description": "Participants receiving Montelukast 0.1 mg inhalation powder"}, {"id": "OG001", "title": "Montelukast 0.3 mg", "description": "Participants receiving Montelukast 0.3 mg inhalation powder"}, {"id": "OG002", "title": "Montelukast 0.3 mg Repeat", "description": "Participants receiving Montelukast 0.3 mg inhalation powder"}, {"id": "OG003", "title": "Montelukast 1 mg", "description": "Participants receiving Montelukast 1 mg inhalation powder"}, {"id": "OG004", "title": "Montelukast 3 mg", "description": "Participants receiving Montelukast 3 mg inhalation powder"}, {"id": "OG005", "title": "Montelukast 10 mg", "description": "Participants receiving Montelukast 10 mg inhalation powder"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "7"}, {"groupId": "OG002", "value": "5"}, {"groupId": "OG003", "value": "6"}, {"groupId": "OG004", "value": "6"}, {"groupId": "OG005", "value": "6"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "NA", "spread": "NA", "comment": "Plasma level below lower limit of quantitation"}, {"groupId": "OG001", "value": "NA", "spread": "NA", "comment": "Plasma level below lower limit of quantitation"}, {"groupId": "OG002", "value": "NA", "spread": "NA", "comment": "Plasma level below lower limit of quantitation"}, {"groupId": "OG003", "value": "155", "spread": "18.5"}, {"groupId": "OG004", "value": "491", "spread": "71"}, {"groupId": "OG005", "value": "1600", "spread": "260"}]}]}]}, {"type": "PRIMARY", "title": "AUC 0-24hr of Montelukast - Multiple Doses", "description": "Blood samples for assessment of AUC 0-24hr were drawn predose and then at specified timepoints (up to 24 hours postdose) on Days 1 and 5 in Part II and on Days 1 and 10 in Part III.", "populationDescription": "Per Protocol Population: All participants who complied with the protocol", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng/mL*hr", "timeFrame": "Up to 24 hours postdose", "groups": [{"id": "OG000", "title": "Montelukast 1 mg", "description": "Participants receiving Montelukast 1 mg inhalation powder QD"}, {"id": "OG001", "title": "Montelukast 3 mg", "description": "Participants receiving Montelukast 3 mg inhalation powder QD"}, {"id": "OG002", "title": "Montelukast 10 mg", "description": "Participants receiving Montelukast 10 mg inhalation powder QD"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "6"}, {"groupId": "OG002", "value": "6"}]}], "classes": [{"title": "Part II Day 1 (n=6)", "categories": [{"measurements": [{"groupId": "OG000", "value": "132", "spread": "43.7"}, {"groupId": "OG001", "value": "403", "spread": "115"}, {"groupId": "OG002", "value": "1576", "spread": "380"}]}]}, {"title": "Part II Day 5 (n=6)", "categories": [{"measurements": [{"groupId": "OG000", "value": "214", "spread": "76.3"}, {"groupId": "OG001", "value": "576", "spread": "148"}, {"groupId": "OG002", "value": "1850", "spread": "304"}]}]}, {"title": "Part III Day 1 (n=6)", "categories": [{"measurements": [{"groupId": "OG000", "value": "NA", "spread": "NA", "comment": "Not obtained in Part III"}, {"groupId": "OG001", "value": "357", "spread": "109"}, {"groupId": "OG002", "value": "1500", "spread": "521"}]}]}, {"title": "Part III Day 10 (n=6)", "categories": [{"measurements": [{"groupId": "OG000", "value": "NA", "spread": "NA", "comment": "Not obtained in Part III"}, {"groupId": "OG001", "value": "526", "spread": "133"}, {"groupId": "OG002", "value": "1880", "spread": "530"}]}]}]}, {"type": "PRIMARY", "title": "Maximum Plasma Concentration (Cmax) of Montelukast - Single Dose", "description": "Blood samples for assessment of Cmax were drawn predose and then at specified timepoints (up to 24 hours postdose) on Day 1 in Part I.", "populationDescription": "Per Protocol Population: All participants who complied with the protocol", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng/mL", "timeFrame": "Up to 24 hours postdose", "groups": [{"id": "OG000", "title": "Montelukast 0.1 mg", "description": "Participants receiving Montelukast 0.1 mg inhalation powder"}, {"id": "OG001", "title": "Montelukast 0.3 mg", "description": "Participants receiving Montelukast 0.3 mg inhalation powder"}, {"id": "OG002", "title": "Montelukast 0.3 mg Repeat", "description": "Participants receiving Montelukast 0.3 mg inhalation powder"}, {"id": "OG003", "title": "Montelukast 1 mg", "description": "Participants receiving Montelukast 1 mg inhalation powder"}, {"id": "OG004", "title": "Montelukast 3 mg", "description": "Participants receiving Montelukast 3 mg inhalation powder"}, {"id": "OG005", "title": "Montelukast 10 mg", "description": "Participants receiving Montelukast 10 mg inhalation powder"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "7"}, {"groupId": "OG002", "value": "5"}, {"groupId": "OG003", "value": "6"}, {"groupId": "OG004", "value": "6"}, {"groupId": "OG005", "value": "6"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "NA", "spread": "NA", "comment": "Plasma level below lower limit of quantitation"}, {"groupId": "OG001", "value": "5.10", "spread": "0.977"}, {"groupId": "OG002", "value": "5.24", "spread": "0.914"}, {"groupId": "OG003", "value": "18.5", "spread": "4.15"}, {"groupId": "OG004", "value": "54.3", "spread": "12.7"}, {"groupId": "OG005", "value": "224", "spread": "47.3"}]}]}]}, {"type": "PRIMARY", "title": "Cmax of Montelukast - Multiple Doses", "description": "Blood samples for assessment of Cmax were drawn predose and then at specified timepoints (up to 24 hours postdose) on Days 1 and 5 in Part II and on Days 1 and 10 in Part III.", "populationDescription": "Per Protocol Population: All participants who complied with the protocol", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng/mL", "timeFrame": "Up to 24 hours postdose", "groups": [{"id": "OG000", "title": "Montelukast 1 mg", "description": "Participants receiving Montelukast 1 mg inhalation powder QD"}, {"id": "OG001", "title": "Montelukast 3 mg", "description": "Participants receiving Montelukast 3 mg inhalation powder QD"}, {"id": "OG002", "title": "Montelukast 10 mg", "description": "Participants receiving Montelukast 10 mg inhalation powder QD"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "6"}, {"groupId": "OG002", "value": "6"}]}], "classes": [{"title": "Part II Day 1 (n=6)", "categories": [{"measurements": [{"groupId": "OG000", "value": "13.8", "spread": "4.96"}, {"groupId": "OG001", "value": "60", "spread": "13.1"}, {"groupId": "OG002", "value": "233", "spread": "30.2"}]}]}, {"title": "Part II Day 5 (n=6)", "categories": [{"measurements": [{"groupId": "OG000", "value": "23.4", "spread": "6.5"}, {"groupId": "OG001", "value": "76", "spread": "15.3"}, {"groupId": "OG002", "value": "242", "spread": "38"}]}]}, {"title": "Part III Day 1 (n=6)", "categories": [{"measurements": [{"groupId": "OG000", "value": "NA", "spread": "NA", "comment": "Not obtained in Part III"}, {"groupId": "OG001", "value": "44.3", "spread": "16.6"}, {"groupId": "OG002", "value": "184", "spread": "66.6"}]}]}, {"title": "Part III Day 10 (n=6)", "categories": [{"measurements": [{"groupId": "OG000", "value": "NA", "spread": "NA", "comment": "Not obtained in Part III"}, {"groupId": "OG001", "value": "64.8", "spread": "13.0"}, {"groupId": "OG002", "value": "225", "spread": "84.7"}]}]}]}, {"type": "PRIMARY", "title": "Time to Cmax (Tmax) of Montelukast - Single Dose", "description": "Blood samples for assessment of Tmax were drawn predose and then at specified timepoints (up to 24 hours postdose) on Day 1 in Part I.", "populationDescription": "Per Protocol Population: All participants who complied with the protocol", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "hours", "timeFrame": "Up to 24 hours postdose", "groups": [{"id": "OG000", "title": "Montelukast 0.1 mg", "description": "Participants receiving Montelukast 0.1 mg inhalation powder"}, {"id": "OG001", "title": "Montelukast 0.3 mg", "description": "Participants receiving Montelukast 0.3 mg inhalation powder"}, {"id": "OG002", "title": "Montelukast 0.3 mg Repeat", "description": "Participants receiving Montelukast 0.3 mg inhalation powder"}, {"id": "OG003", "title": "Montelukast 1 mg", "description": "Participants receiving Montelukast 1 mg inhalation powder"}, {"id": "OG004", "title": "Montelukast 3 mg", "description": "Participants receiving Montelukast 3 mg inhalation powder"}, {"id": "OG005", "title": "Montelukast 10 mg", "description": "Participants receiving Montelukast 10 mg inhalation powder"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "7"}, {"groupId": "OG002", "value": "5"}, {"groupId": "OG003", "value": "6"}, {"groupId": "OG004", "value": "6"}, {"groupId": "OG005", "value": "6"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "Plasma level below lower limit of quantitation"}, {"groupId": "OG001", "value": "2.5", "lowerLimit": "0.8", "upperLimit": "4.0"}, {"groupId": "OG002", "value": "4.0", "lowerLimit": "0.5", "upperLimit": "4.0"}, {"groupId": "OG003", "value": "2.4", "lowerLimit": "0.5", "upperLimit": "7.0"}, {"groupId": "OG004", "value": "0.8", "lowerLimit": "0.5", "upperLimit": "4.0"}, {"groupId": "OG005", "value": "0.5", "lowerLimit": "0.5", "upperLimit": "4.0"}]}]}]}, {"type": "PRIMARY", "title": "Tmax of Montelukast - Multiple Doses", "description": "Blood samples for assessment of Tmax were drawn predose and then at specified timepoints (up to 24 hours postdose) on Days 1 and 5 in Part II and on Days 1 and 10 in Part III.", "populationDescription": "Per Protocol Population: All participants who complied with the protocol", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "hours", "timeFrame": "Up to 24 hours postdose", "groups": [{"id": "OG000", "title": "Montelukast 1 mg", "description": "Participants receiving Montelukast 1 mg inhalation powder QD"}, {"id": "OG001", "title": "Montelukast 3 mg", "description": "Participants receiving Montelukast 3 mg inhalation powder QD"}, {"id": "OG002", "title": "Montelukast 10 mg", "description": "Participants receiving Montelukast 10 mg inhalation powder QD"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "6"}, {"groupId": "OG002", "value": "6"}]}], "classes": [{"title": "Part II Day 1 (n=6)", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.4", "lowerLimit": "0.7", "upperLimit": "7"}, {"groupId": "OG001", "value": "0.5", "lowerLimit": "0.5", "upperLimit": "0.7"}, {"groupId": "OG002", "value": "0.5", "lowerLimit": "0.5", "upperLimit": "0.7"}]}]}, {"title": "Part II Day 5 (n=6)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.7", "lowerLimit": "0.5", "upperLimit": "0.7"}, {"groupId": "OG001", "value": "0.5", "lowerLimit": "0.5", "upperLimit": "0.7"}, {"groupId": "OG002", "value": "0.6", "lowerLimit": "0.5", "upperLimit": "1.0"}]}]}, {"title": "Part III Day 1 (n=6)", "categories": [{"measurements": [{"groupId": "OG000", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "Not obtained in Part III"}, {"groupId": "OG001", "value": "0.5", "lowerLimit": "0.5", "upperLimit": "4.0"}, {"groupId": "OG002", "value": "0.5", "lowerLimit": "0.2", "upperLimit": "7"}]}]}, {"title": "Part III Day 10 (n=6)", "categories": [{"measurements": [{"groupId": "OG000", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "Not obtained in Part III"}, {"groupId": "OG001", "value": "0.5", "lowerLimit": "0.2", "upperLimit": "0.7"}, {"groupId": "OG002", "value": "0.5", "lowerLimit": "0.5", "upperLimit": "0.7"}]}]}]}, {"type": "PRIMARY", "title": "Apparent Terminal Half Life (t1/2) of Montelukast - Single Dose", "description": "Blood samples for assessment of t1/2 were drawn predose and then at specified timepoints (up to 24 hours postdose) on Day 1 in Part I.", "populationDescription": "Per Protocol Population: All participants who complied with the protocol", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "hours", "timeFrame": "Up to 24 hours postdose", "groups": [{"id": "OG000", "title": "Montelukast 0.1 mg", "description": "Participants receiving Montelukast 0.1 mg inhalation powder"}, {"id": "OG001", "title": "Montelukast 0.3 mg", "description": "Participants receiving Montelukast 0.3 mg inhalation powder"}, {"id": "OG002", "title": "Montelukast 0.3 mg Repeat", "description": "Participants receiving Montelukast 0.3 mg inhalation powder"}, {"id": "OG003", "title": "Montelukast 1 mg", "description": "Participants receiving Montelukast 1 mg inhalation powder"}, {"id": "OG004", "title": "Montelukast 3 mg", "description": "Participants receiving Montelukast 3 mg inhalation powder"}, {"id": "OG005", "title": "Montelukast 10 mg", "description": "Participants receiving Montelukast 10 mg inhalation powder"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "7"}, {"groupId": "OG002", "value": "5"}, {"groupId": "OG003", "value": "6"}, {"groupId": "OG004", "value": "6"}, {"groupId": "OG005", "value": "6"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "NA", "spread": "NA", "comment": "Plasma level below lower limit of quantitation"}, {"groupId": "OG001", "value": "NA", "spread": "NA", "comment": "Plasma level below lower limit of quantitation"}, {"groupId": "OG002", "value": "NA", "spread": "NA", "comment": "Plasma level below lower limit of quantitation"}, {"groupId": "OG003", "value": "5.7", "spread": "2.1"}, {"groupId": "OG004", "value": "6.9", "spread": "0.9"}, {"groupId": "OG005", "value": "5.7", "spread": "0.5"}]}]}]}, {"type": "PRIMARY", "title": "t1/2 of Montelukast - Multiple Doses", "description": "Blood samples for assessment of t1/2 were drawn predose and then at specified timepoints (up to 24 hours postdose) on Days 1 and 5 in Part II and on Days 1 and 10 in Part III.", "populationDescription": "Per Protocol Population: All participants who complied with the protocol", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "hours", "timeFrame": "Up to 24 hours postdose", "groups": [{"id": "OG000", "title": "Montelukast 1 mg", "description": "Participants receiving Montelukast 1 mg inhalation powder QD"}, {"id": "OG001", "title": "Montelukast 3 mg", "description": "Participants receiving Montelukast 3 mg inhalation powder QD"}, {"id": "OG002", "title": "Montelukast 10 mg", "description": "Participants receiving Montelukast 10 mg inhalation powder QD"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "6"}, {"groupId": "OG002", "value": "6"}]}], "classes": [{"title": "Part II Day 5 (n=6)", "categories": [{"measurements": [{"groupId": "OG000", "value": "8.2", "spread": "2.5"}, {"groupId": "OG001", "value": "7.6", "spread": "2.5"}, {"groupId": "OG002", "value": "7.7", "spread": "2.4"}]}]}, {"title": "Part III Day 10 (n=6)", "categories": [{"measurements": [{"groupId": "OG000", "value": "NA", "spread": "NA", "comment": "Not obtained in Part III"}, {"groupId": "OG001", "value": "8.1", "spread": "1.4"}, {"groupId": "OG002", "value": "7.4", "spread": "1.7"}]}]}]}, {"type": "PRIMARY", "title": "AUC 0-24hr Accumulation Ratio of Montelukast - Multiple Doses", "description": "The AUC 0-24hr Accumulation Ratio of Montelukast was calculated as the geometric mean ratio of AUC 0-24hr on the last day and the first day of a multiple dose regimen: Day 5/Day 1 in Part II and Day 10/Day 1 in Part III.", "populationDescription": "Per Protocol Population: All participants who complied with the protocol", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "ratio", "timeFrame": "up to 10 days after first dose of study drug", "groups": [{"id": "OG000", "title": "Montelukast 1 mg", "description": "Participants receiving Montelukast 1 mg inhalation powder QD"}, {"id": "OG001", "title": "Montelukast 3 mg", "description": "Participants receiving Montelukast 3 mg inhalation powder QD"}, {"id": "OG002", "title": "Montelukast 10 mg", "description": "Participants receiving Montelukast 10 mg inhalation powder QD"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "6"}, {"groupId": "OG002", "value": "6"}]}], "classes": [{"title": "Part II (n=6)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.61"}, {"groupId": "OG001", "value": "1.44"}, {"groupId": "OG002", "value": "1.2"}]}]}, {"title": "Part III (n=6)", "categories": [{"measurements": [{"groupId": "OG000", "value": "NA", "comment": "Not obtained in Part III"}, {"groupId": "OG001", "value": "1.19"}, {"groupId": "OG002", "value": "1.26"}]}]}]}, {"type": "PRIMARY", "title": "Cmax Accumulation Ratio of Montelukast - Multiple Doses", "description": "The Cmax Accumulation Ratio of Montelukast was calculated as the geometric mean ratio of Cmax on the last day and the first day of a multiple dose regimen: Day 5/Day 1 in Part II and Day 10/Day 1 in Part III.", "populationDescription": "Per Protocol Population: All participants who complied with the protocol", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "ratio", "timeFrame": "up to 10 days after first dose of study drug", "groups": [{"id": "OG000", "title": "Montelukast 1 mg", "description": "Participants receiving Montelukast 1 mg inhalation powder QD"}, {"id": "OG001", "title": "Montelukast 3 mg", "description": "Participants receiving Montelukast 3 mg inhalation powder QD"}, {"id": "OG002", "title": "Montelukast 10 mg", "description": "Participants receiving Montelukast 10 mg inhalation powder QD"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "6"}, {"groupId": "OG002", "value": "6"}]}], "classes": [{"title": "Part II (n=6)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.73"}, {"groupId": "OG001", "value": "1.27"}, {"groupId": "OG002", "value": "1.03"}]}]}, {"title": "Part III (n=6)", "categories": [{"measurements": [{"groupId": "OG000", "value": "NA", "comment": "Not obtained in Part III"}, {"groupId": "OG001", "value": "1.03"}, {"groupId": "OG002", "value": "1.22"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Up to 14 days after last dose of study drug", "description": "Safety Population: All participants who received at least one dose of study drug", "eventGroups": [{"id": "EG000", "title": "Montelukast 0.1 mg", "description": "Participants receiving Montelukast 0.1 mg inhalation powder", "seriousNumAffected": 0, "seriousNumAtRisk": 7, "otherNumAffected": 2, "otherNumAtRisk": 7}, {"id": "EG001", "title": "Montelukast 0.3 mg", "description": "Participants receiving Montelukast 0.3 mg inhalation powder", "seriousNumAffected": 0, "seriousNumAtRisk": 7, "otherNumAffected": 4, "otherNumAtRisk": 7}, {"id": "EG002", "title": "Montelukast 1 mg", "description": "Participants receiving Montelukast 1 mg inhalation powder", "seriousNumAffected": 0, "seriousNumAtRisk": 12, "otherNumAffected": 6, "otherNumAtRisk": 12}, {"id": "EG003", "title": "Montelukast 3 mg", "description": "Participants receiving Montelukast 3 mg inhalation powder", "seriousNumAffected": 0, "seriousNumAtRisk": 18, "otherNumAffected": 9, "otherNumAtRisk": 18}, {"id": "EG004", "title": "Montelukast 10 mg", "description": "Participants receiving Montelukast 10 mg inhalation powder", "seriousNumAffected": 0, "seriousNumAtRisk": 19, "otherNumAffected": 5, "otherNumAtRisk": 19}, {"id": "EG005", "title": "Placebo", "description": "Participants receiving Placebo inhalation powder", "seriousNumAffected": 0, "seriousNumAtRisk": 18, "otherNumAffected": 6, "otherNumAtRisk": 18}], "otherEvents": [{"term": "Abdominal Pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 18}]}, {"term": "Constipation", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 18}]}, {"term": "Dyspepsia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 18}]}, {"term": "Gastrooesophageal Reflux Disease", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 7}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 18}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 18}]}, {"term": "Paraesthesia Oral", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 18}]}, {"term": "Toothache", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 18}]}, {"term": "Chest Discomfort", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 18}]}, {"term": "Chest Pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 7}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 18}]}, {"term": "Fatigue", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 18}]}, {"term": "Herpes Simplex", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 18}]}, {"term": "Laryngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 7}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 18}]}, {"term": "Rhinitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 7}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 18}]}, {"term": "Sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 18}]}, {"term": "Vaginal Infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 19}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 18}]}, {"term": "Foot Fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 18}]}, {"term": "Alanine Aminotransferase Increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 18}]}, {"term": "Aspartate Aminotransferase Increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 18}]}, {"term": "Blood Bilirubin Increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 18}]}, {"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 18}]}, {"term": "Back Pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 18}]}, {"term": "Musculoskeletal Chest Pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG004", "numAffected": 2, "numAtRisk": 19}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 18}]}, {"term": "Myalgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 18}]}, {"term": "Pain in Extremity", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 18}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 7}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 18}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 18}]}, {"term": "Dysgeusia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 7}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG002", "numAffected": 5, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 3, "numAtRisk": 18}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 18}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 3, "numAtRisk": 18}, {"groupId": "EG004", "numAffected": 2, "numAtRisk": 19}, {"groupId": "EG005", "numAffected": 3, "numAtRisk": 18}]}, {"term": "Lethargy", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 18}]}, {"term": "Apnoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 7}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 18}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 7}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG005", "numAffected": 2, "numAtRisk": 18}]}, {"term": "Dyspnoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 18}]}, {"term": "Haemoptysis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 7}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 18}]}, {"term": "Oropharyngeal Pain", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 19}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 18}]}, {"term": "Respiratory Tract Congestion", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 19}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 18}]}, {"term": "Throat Irritation", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 18}]}, {"term": "Wheezing", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 18}]}, {"term": "Periorbital Oedema", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 18}]}, {"term": "Urticaria", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 18}]}, {"term": "Flushing", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 19}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 18}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission."}, "pointOfContact": {"title": "Senior Vice President,Global Clinical Development", "organization": "Merck Sharp & Dohme Corp", "email": "ClinicalTrialsDisclosure@merck.com", "phone": "1-800-672-6372"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["United States"]}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M27137", "name": "Respiratory Aspiration", "relevance": "LOW"}, {"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC20", "name": "Immune System Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "C000093875", "term": "Montelukast"}], "ancestors": [{"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000020024", "term": "Leukotriene Antagonists"}, {"id": "D000006727", "term": "Hormone Antagonists"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000065694", "term": "Cytochrome P-450 CYP1A2 Inducers"}, {"id": "D000065693", "term": "Cytochrome P-450 Enzyme Inducers"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M274108", "name": "Montelukast", "asFound": "Means", "relevance": "HIGH"}, {"id": "M128948", "name": "Immunoferon", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M21876", "name": "Leukotriene Antagonists", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}